Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | H3B-5942 + PKI-402 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
H3B-5942 | CS-0047696 | Hormone - Anti-estrogens 29 | H3B-5942 is a selective estrogen receptor covalent antagonist, which antagonizes wild-type and mutant forms of estrogen receptor alpha, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 29991605). | |
PKI-402 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | PKI-402 is a dual ATP-competitive mTOR/PI3K inhibitor, which leads to reduced downstream signaling, potentially resulting in decreased tumor growth (PMID: 20371716, PMID: 32585451). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|